Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 28, 2023

BUY
$7.03 - $11.53 $80,345 - $131,776
11,429 New
11,429 $83,000
Q3 2022

Oct 25, 2022

BUY
$12.16 - $19.42 $2,894 - $4,621
238 Added 1.13%
21,373 $262,000
Q2 2022

Aug 03, 2022

SELL
$9.99 - $21.35 $87,832 - $187,709
-8,792 Reduced 29.38%
21,135 $263,000
Q1 2022

May 04, 2022

BUY
$14.08 - $27.63 $125,213 - $245,713
8,893 Added 42.28%
29,927 $569,000
Q4 2021

Jan 27, 2022

SELL
$26.55 - $40.57 $187,549 - $286,586
-7,064 Reduced 25.14%
21,034 $558,000
Q3 2021

Oct 29, 2021

BUY
$39.27 - $72.94 $705,367 - $1.31 Million
17,962 Added 177.21%
28,098 $1.15 Million
Q2 2021

Jul 26, 2021

BUY
$31.29 - $56.64 $122,343 - $221,462
3,910 Added 62.8%
10,136 $574,000
Q1 2021

Apr 27, 2021

BUY
$39.71 - $90.58 $247,234 - $563,951
6,226 New
6,226 $261,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $118M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.